Actinium Pharmaceuticals’ (ATNM) “Buy” Rating Reiterated at HC Wainwright

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $4.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 129.89% from the company’s current price.

Actinium Pharmaceuticals Stock Up 16.8 %

Actinium Pharmaceuticals stock traded up $0.25 during trading hours on Tuesday, hitting $1.74. 3,622,118 shares of the company traded hands, compared to its average volume of 280,600. The firm’s 50-day simple moving average is $1.21 and its two-hundred day simple moving average is $1.45. The firm has a market cap of $54.28 million, a P/E ratio of -1.25 and a beta of 0.10. Actinium Pharmaceuticals has a 1-year low of $1.03 and a 1-year high of $10.24.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ATNM. Geode Capital Management LLC boosted its stake in Actinium Pharmaceuticals by 3.0% during the third quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock valued at $1,290,000 after buying an additional 19,843 shares in the last quarter. Northern Trust Corp lifted its position in shares of Actinium Pharmaceuticals by 4.9% during the 4th quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock valued at $317,000 after acquiring an additional 11,812 shares during the last quarter. Los Angeles Capital Management LLC grew its holdings in shares of Actinium Pharmaceuticals by 25.0% in the 4th quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock worth $270,000 after acquiring an additional 42,770 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Actinium Pharmaceuticals by 49.9% in the 4th quarter. Renaissance Technologies LLC now owns 190,400 shares of the company’s stock valued at $240,000 after purchasing an additional 63,400 shares during the period. Finally, Squarepoint Ops LLC raised its holdings in shares of Actinium Pharmaceuticals by 25.4% during the fourth quarter. Squarepoint Ops LLC now owns 183,262 shares of the company’s stock valued at $231,000 after acquiring an additional 37,159 shares during the period. 27.50% of the stock is owned by institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).